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Aims To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiogra-
phy (CAG)+ad hoc percutaneous coronary intervention (PCI).
Methods
and results
Open-trial randomized 1028 patients with stable angina to group A (‘non-selective’—clopidogrel 600 mg .6h
before CAG; n ¼ 513) or group B (‘selective’—clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;
n ¼ 515). Combined primary endpoint was death/periprocedural myocardial infarction (MI)/stroke/re-intervention
within 7 days. Secondary endpoints were troponin elevation and bleeding complications. Primary endpoint occurred
in 0.8% group A patients vs. 1% group B (P ¼ 0.749; 90% CI for the percentage difference 21.2–0.8). Periprocedural
troponin elevation (.3  ULN) was detected in 2.6% group A vs. 3.3% group B (P ¼ 0.475; 90% CI 22.5–1.0).
Bleeding complications occurred in 3.5% group A patients vs. 1.4% group B (P ¼ 0.025). After adjustment for
covariates and factors that may inﬂuence the bleeding risk, patients in group A were shown to have more likely
bleeding complications when compared with group B (OR ¼ 3.03; 95% CI 1.14–8.10; P ¼ 0.027).
Conclusion High (600 mg) loading dose of clopidogrel before elective CAG increased the risk of minor bleeding complications,
while the beneﬁt on periprocedural infarction was not signiﬁcant. Clopidogrel can be given safely in the catheteriza-
tion laboratory between CAG and PCI in chronic stable angina patients.
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The introduction of thienopyridines to interventional cardiology 13
years ago triggered a revolutionary change—it made coronary
stent implantation a safe procedure: the risk of stent thrombosis
decreased from 8% (with the old complex anticoagulation
regimen) to 1–2% (with thienopyridine and aspirin) and the risk
of signiﬁcant bleeding complications decreased from 5 to
1–2%.
1,2 Ticlopidine and later clopidogrel
3 became a routine
part of every percutaneous coronary intervention (PCI). Later,
the CREDO
4 and PCI-CURE
5 trials showed that the patients pre-
treated with clopidogrel have a lower risk of periprocedural
ischaemic events. Clopidogrel became widely used for patients
undergoing PCI. However, the loading dose given before PCI
varies among different clinical trials and different hospitals. The
approved loading dose is 300 mg. However, 600 mg loading dose
was shown to be superior in a small randomized trial
6 and is
used with increasing frequency with supporting data from trials
in acute coronary syndromes.
7–10 These two loading doses are
compared in the ongoing large randomized multicentre trial
CURRENT/OASIS-7.
11 Recommended time for the loading dose
is .6 h before PCI. However, nearly all PCIs are currently per-
formed as ‘ad hoc’ procedures [i.e. immediately following the diag-
nostic coronary angiography (CAG)], and thus the time between
the decision to intervene and PCI procedure is just a few
minutes. Due to this fact, some hospitals administer the loading
dose of clopidogrel in advance to all patients undergoing CAG,
others administer it during the procedure (i.e. after CAG) only
to those undergoing PCI. It has not been established yet which
of these strategies is better. Most Czech PCI centres have been
using clopidogrel before PCI ‘selectively’ (i.e. in the cath-lab
between CAG and PCI or even after PCI) in their routine practice
for many years. When the new ESC guidelines for PCI were pub-
lished in 2005, ﬁve study centres decided to compare their routi-
nely used ‘old selective’ strategy with the ESC guidelines
recommended ‘new non-selective’ strategy and the PRAGUE-8
trial design was born.
The hypothetical advantage of the ‘non-selective’ approach (clo-
pidogrel .6 h before each elective CAG) is the full drug effect
during ad hoc PCI resulting in a lower rate of ischaemic periproce-
dural complications. The disadvantage of this approach might be
the increased risk of periprocedural bleeding complications,
especially difﬁcult to justify among stable angina patients, who in
fact had no indication for clopidogrel (i.e. those, who underwent
only CAG, but not PCI).
The hypothetical advantage of the ‘selective’ approach (clopido-
grel on the catheterization table, just after CAG/a few minutes
prior to PCI) is that clopidogrel is given only to those patients
who have a clear indication (i.e. really undergo PCI) and the bleeding
risk thus may be reduced. The disadvantage might be the increase of
ischaemic periprocedural complications due to the fact that the full
effect of clopidogrel is not yet achieved at the time of PCI.
Methods
The trial protocol, case report form, and written patient informed
consent were approved by the local ethical committees of all
participating institutions. The trial was registered at www.clinical-
trials.gov under registration number NCT00432120.
Patients and treatment arms
A total of 9195 patients underwent elective CAG during the study
period in the participating centres. The inclusion/exclusion criteria as
well as the speciﬁc numbers of patients excluded due to a given cri-
terion are listed in Table 1. A total of 5055 patients fulﬁlled all the cri-
teria, 4027 of them were not included merely due to logistic reasons
(low study budget and stafﬁng). In general, patients undergoing planned
elective CAG for suspected or proven coronary artery disease (either
chronic stable or stabilized unstable) were enrolled the day before the
procedure after they signed written informed consent.
Randomization was carried out using the centralized sealed envel-
opes method, coordinated at the 3rd Medical Faculty, Prague. The
study was conducted on an open basis: neither the patients nor the
investigators were blinded to the treatment arm. The statistician
(who analysed all the data and provided the results) was blinded to
the treatment arms. Study enrolment began in March 2006 and
ended in July 2007. A total of 1028 patients were randomized in
two groups: 513 patients in group A and 515 patients in group B
(Figure 1). All patients in group A received clopidogrel 600 mg orally
more than 6 h before CAG. In group A, the mean duration between
clopidogrel administration and CAG was 20.6 h (median 20 h). From
these, 30% underwent PCI and 70% patients underwent only CAG.
Only patients undergoing PCI (n ¼ 143, i.e. 28%) in group B received
clopidogrel 600 mg orally in the catheterization laboratory after CAG
a few minutes prior to PCI. The remaining 72% patients in group B did
................................................................................
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Elective CAG for suspected or
proven coronary artery
disease (stable forms or fully
stabilized acute coronary
syndrome)
Thienopyridine treatment in
previous 2 weeks (25 patients
excluded due to this reason)
Signed written informed
consent (48 patients
excluded for signature
refusal)
Contraindication for clopidogrel (0
patient excluded due to this
reason)
Age   18 years (0 patient
excluded)
CAG scheduled less than 6 h after
potential randomization (3627
patients excluded due to this
reason)
Clinically signiﬁcant bleeding
(i.e. with haemoglobin fall by
.50 g/L and/or requiring
transfusions or surgery) in
previous 3 months (85 patients
excluded due to this reason)
Participation in any project with
investigational drug or device
within previous 1 month (355
patients excluded due to this
reason)
Additional 4027 patients excluded
due to the logistic reasons (see
Methods section)
P. Widimsky ´ et al 1496not receive any clopidogrel due to the fact that no PCI was indicated
after CAG. Patients’ baseline characteristics are shown in Table 2.
Invasive procedures
Cardiac catheterization procedures were performed via femoral
approach using 5F or 6F sheaths and catheters. All technical aspects
(including the use and dose of periprocedural heparin) of the pro-
cedure were left at the discretion of treating cardiologist as per local
routine. All participating hospitals use routinely the ‘ad hoc PCI strat-
egy’: when elective CAG shows a ﬁnding suitable for PCI (mostly
single-vessel or double-vessel disease), intervention follows immedi-
ately after CAG. Staged procedures (i.e. CAG and PCI in two different
days) were used only for 16 patients (i.e. 5% of all PCIs) with multives-
sel disease, who have been discussed during the heart team meeting
and were found to be poor candidates for coronary artery bypass
graft (CABG) surgery.
Examinations and follow-up
The laboratory examinations at baseline were done as per local
routine and included Na, K, urea, serum creatinine, AST, ALT,
CK-MB, troponin I, blood count, INR, and APTT. Left ventricular ejec-
tion fraction was assessed by echocardiography or left ventriculogra-
phy as per local routine in each centre. CAG was done in all
patients. Electrocardiogram was recorded at baseline and after CAG/
PCI. CK-MB and troponin I were analysed 8–16 h after PCI. Patients
were followed until their discharge from the hospital or until day 7,
whatever occurred earlier.
Endpoints
Primary endpoint was the ﬁrst clinical occurrence of any of the follow-
ing: death/periprocedural MI/stroke or transient ischaemic attack/
re-intervention within 7 days. Secondary endpoints were periproce-
dural troponin elevation (.3  ULN), TIMI-ﬂow after PCI, bleeding
complications, and each individual component of the combined
primary endpoint.
Death was deﬁned as mortality from any cause (cardiovascular or
non-vascular).
Periprocedural MI was deﬁned as the post-procedural (after PCI)
elevation of the serum levels of CK-MB to at least three times the
upper limit of normal values in two samples collected at different
sampling times. Stroke (of any cause) was deﬁned as new focal neuro-
logical deﬁcit occurring within 24 h after CAG and persisting more
than 24 h. Transient ischaemic attack was deﬁned similarly to stroke,
but persisting less than 24 h. Re-intervention was deﬁned as new
ischaemic symptoms leading to repeat CAG and/or PCI/or CABG
within 7 days.
Bleeding complications were deﬁned as: (i) major bleeding, intracra-
nial bleeding or clinically overt bleeding associated with a decrease in
haemoglobin .50 g/L; (ii) minor bleeding, clinically visible with a
decrease in haemoglobin  50 g/L according to the modiﬁed criteria
of thrombolysis in myocardial infarction (TIMI).
12 Besides this interna-
tionally recognized deﬁnition, we speciﬁcally registered those bleeding
complications resulting in prolonged hospital stay (classiﬁed as major or
minor) and those resulting in surgical intervention. Bleeding related to
CABG was deﬁned as bleeding that met the criteria for major bleeding
events according to the TIMI criteria (with a drop in haemoglobin of
.50 g/L) and associated with a surgical procedure. CABG-related
bleeding was evaluated separately. The diagnosis of intracranial bleed-
ing required conﬁrmation by computed tomography or magnetic
resonance imaging. Small femoral access haematomas not requiring
treatment was also registered.
Statistical methods
The initial assumption was that the endpoint will occur in 3% of group
B patients. The trial was designed to have 80% power to detect a 2.5%
absolute decrease (i.e. 0.5% incidence) of the primary endpoint in
group A as signiﬁcantly different from that in group B at a signiﬁcance
level of 0.05. On this basis, 508 patients were required in each group.
Primary treatment comparison was based on the data from all 1028
subjects with stable angina randomized into group A or B. Patients
undergoing PCI and patients with CABG, respectively, formed the
two analysis sets of secondary interest. Values of continuous variables
are presented as arithmetic means and Student’s two-sample t-test was
used to evaluate between-group comparisons. For dichotomous data,
the percentages are given and differences in proportions between
groups were analysed using Fisher’s exact test and Pearson’s x
2 test
in the four-fold table. Test results with P-value equal to or less than
0.05 were considered statistically signiﬁcant. According to Hauck,
13
the equivalence of both groups may be assessed using 90% conﬁdence
Figure 1 Study patients and the treatment used.
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and B.
The logistic regression model was used to adjust the differences in
bleeding complications for covariate effects. Following factors and covari-
ates were entered in the model: age, gender, BMI, renal insufﬁciency, full
anticoagulant dose of heparin (UFH or enoxaparin), treatment with GP
IIb/IIIa inhibitors, indicator for INR .1.3, and indicator for platelet
count , 100   10
9 per litre. For continuous variables, the assumption
of linearity in logit was checked using the Box-Tidwell approach and
logit graphs constructed for a banded version of an underlying continu-
ous variable. No violations of linearity assumption were identiﬁed.
Statistical analysis was performed by statistical software Stata,
release 9 (Stata Corp. LP, College Station, TX, USA).
Results
Revascularizations
Ad hoc PCI was performed in 29% of study patients (30% in group
A vs. 28% in group B) and bypass surgery (CABG) in 12% of
patients (mostly after .7 days) (Figure 1). Medical therapy was
recommended in 59% of patients (22% had at least single vessel
disease, 37% had either non-signiﬁcant lesions or no residual
stenosis after previous revascularization or normal coronary
angiogram).
Endpoints among all study patients
Primary endpoint occurred in 0.8% of group A patients vs. 1% of
group B patients (P ¼ 0.749; 90% CI for difference in percentages
21.2–0.8) (Table 3). Periprocedural troponin elevation (.3 
ULN) was detected in 2.6% of patients in group A vs. 3.3% in
group B (P ¼ 0.475; 90% CI 22.5–1.0) (Figure 2). Bleeding compli-
cations (Table 4) occurred in 3.5% of group A patients vs. 1.4% of
group B patients (P ¼ 0.025) (Figure 3). After adjustment for
speciﬁed covariates and factors that may inﬂuence the bleeding
risk (see Methods section), patients in group A were shown to
have more likely bleeding complications when compared with
group B (OR ¼ 3.03; 95% CI 1.14–8.10; P ¼ 0.027). Statistically
signiﬁcant risk factors were also female gender (P ¼ 0.001) and
...............................................................................................................................................................................
Table 2 Patients baseline clinical and laboratory characteristics
Group A (non-selective clopidogrel
before CAG)
Group B (selective clopidogrel
before PCI)
P-value
n 513 515
Age (year) 65.3 (9.6) 65.9 (9.6) 0.257
Females 183 (36%) 194 (39%) 0.506
Body weight (kg) 84.6 (15.8) 83.3 (14.9) 0.208
Stabilized ACS 66 (13%) 79 (15%) 0.249
Proven or suspected chronic stable CAD 446 (87%) 434 (85%) 0.249
Previous MI 137 (27%) 147 (29%) 0.497
Hypercholesterolaemia 335 (65%) 342 (67%) 0.676
Hypertension 405 (79%) 407 (79%) 0.926
Smoking (current or past) 123 (24%) 126 (25%) 0.841
Diabetes mellitus 147 (29%) 147 (29%) 0.984
Previous revascularization (PCI or CABG) 106 (21%) 117 (23%) 0.414
Known chronic renal failure 38 (7%) 35 (7%) 0.709
Treatment with ASA within 1 week before
randomization
375 (73%) 403 (79%) 0.047
Anticoagulant therapy within 1 week before
randomization
33 (6.5%) 33 (6.0%) 0.993
Treatment with GP IIb/IIIa inhibitors as an adjunct
during PCI
1 (0.2%) 2 (0.4%) 0.608
Treatment with statins within 1 week before
randomization
291 (57%) 296 (58%) 0.780
Mean platelet count 241 (74) 242 (65) 0.836
White cells count 7.7 (2.2) 7.8 (2.2) 0.688
Red cells count 4.6 (0.6) 4.6 (0.5) 0.219
INR at randomization 1.06 (0.12) 1.05 (0.12) 0.123
APTT at randomization (s) 34.5 (12.7) 33.9 (11.4) 0.496
Creatinine (mmol/L) 93.8 (26.6) 93.8 (31.4) 0.981
Ejection fraction (%) 56.8 (11.1) 57.1 (11.1) 0.654
Continuous variables are presented as means and standard deviations and categorical data are presented as absolute frequencies (counts) and percentages.
P. Widimsky ´ et al 1498use of GP IIb/IIIa inhibitors (P ¼ 0.027). Low thrombocyte levels
showed P-value close to signiﬁcance level (P ¼ 0.091).
Endpoints among patients who
underwent percutaneous coronary
intervention
When only the subgroup of patients who underwent PCI was ana-
lysed, primary endpoint occurred in 1.3% group A vs. 2.8% group
B( P ¼ 0.432; 90% CI 24.1–1.2). Periprocedural troponin
elevation (.3  ULN) was detected in 8.4% (group A) vs.
11.9% (group B, P ¼ 0.316; 90% CI 22.3–9.3). TIMI-ﬂow ,3
after PCI was in 1.3% group A vs. 0% group B (P ¼ 0.499).
Bleeding complications occurred in 7.1% (group A) vs. 0.7%
(group B, P ¼ 0.006) and re-intervention within 7 days in 0.7%
group A vs. 1.4% group B (P ¼ 0.515).
Patients who underwent coronary
artery bypass graft
CABG was performed in 122 patients. Only 17 of them (14% from
those indicated for CABG and 1.7% from all CAG) underwent
CABG within 1 week after CAG (7 in group A and 10 in group
B). There was only one clinically overt peri-operative bleeding
complication among these 17 patients and two other patients
had haemoglobin decrease by .50 g/L postoperatively without
any postoperative bleeding.
Discussion
Clopidogrel loading dose
Theregisteredloadingdoseforclopidogrelis300 mgandthisdosewas
usedfor many years before elective PCIs. In therecentyears, there has
Figure 2 Periprocedural troponin elevation (.3  ULN, per cent of patients).
...............................................................................................................................................................................
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Table 3 Periprocedural ischaemic events in both groups
Group A (non-selective
clopidogrel before CAG)
Group B (selective
clopidogrel before PCI)
P-value
All study patients n ¼ 513 n ¼ 515
Death of any cause 1 (0.2%) 0 (0.0%) 0.498
Periprocedural MI (CK-MB .3  ULN) 0 0 1.000
Periprocedural stroke/TIA 1 (0.2%) 3 (0.6%) 0.624
Re-intervention 2 (0.4%) 2 (0.4%) 0.992
Primary endpoint 4 (0.8%) 5 (1.0%) 0.749
Periprocedural troponin increase .3  ULN 13 (2.7%) 17 (3.3%) 0.475
Death of any cause/periprocedural troponin increase .3 
ULN/periprocedural stroke/TIA/re-intervention
17 (3.3%) 19 (3.7%) 0.757
Only patients, who underwent PCI n ¼ 155 (30.3%) n ¼ 143 (27.9%) 0.398
Primary endpoint 2 (1.3%) 4 (2.8%) 0.432
Periprocedural troponin elevation .3  ULN 13 (8.4%) 17 (11.9%) 0.316
Impairment of TIMI-ﬂow to ,3 after PCI 2 (1.3%) 0 0.499
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the ARMYDA-2 trial.
6 Most data supporting this higher loading dose
originate from acute coronary syndrome patients.
8–10 Fewer data
are available on chronic stable coronary artery disease patients.
Despite the fact that a recent retrospective registry showed (unlike
ARMYDA-2 randomized trial) no beneﬁt from 600 mg over 300 mg
doseinPCIforchronicstablecoronaryarterydisease,
14manyhospitals
around the world (as well as most Czech PCI centres) use 600 mg
routinely for pre-treatment before PCI. Thus, 600 mg loading dose
was selected also for this randomized study.
Timing of the loading dose
The pre-treatment (within 3–24 h) hypothesis failed to be
validated in the prospective randomized Clopidogrel for the
Reduction of Events During Observation
4 trial. No treatment
differences were observed in patients receiving a 600 mg loading
dose 2–3 h before PCI vs. those receiving the same loading dose
12 h before PCI in the Intracoronary Stenting and Antithrombotic
Regimen–Rapid Early Action for Coronary Treatment (ISAR–
REACT) trial.
15 The European Society of Cardiology (ESC)
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 4 Bleeding complications in both groups
Group A (non-selective clopidogrel
before CAG)
Group B (selective clopidogrel
before PCI)
P-value
All study patients (all CAGs) n ¼ 513 n ¼ 515
Major and minor bleeding complications 18 (3.5%) 7 (1.4%) 0.025
Major (intracranial or HB fall by .50 g/L) 2 (0.4%) 1 (0.2%) 0.624
Minor (clinically overt, prolonging hospital stay) 16 (3.1%) 6 (1.2%) 0.033
Breakdown of all bleeding complications
(major/minor)
Intracranial 1 (0.2%) 0 (0.0%) 0.498
Retroperitoneal 2 (0.4%) 0 (0.0%) 0.248
Gastrointestinal 1 (0.2%) 0 (0.0%) 0.498
Femoral access bleeding requiring transfusion
and/or surgical repair
0 (0.0%) 0 (0.0%) 1.000
Femoral access bleeding requiring prolonged
compression
8 (1.6%) 5 (1.0%) 0.419
Large superﬁcial haematoma 5 (1.0%) 1 (0.2%) 0.122
Not included in major or minor
Small femoral access haematomas 18 (3.5%) 9 (1.8%) 0.082
Only patients, who underwent PCI n ¼ 155 n ¼ 143 0.398
Major and minor bleeding complications 11 (7.1%) 1 (0.7%) 0.006
Major (intracranial or HB fall by .50 g/L) 1 (0.6%) 1 (0.7%) 0.954
Minor (clinically overt, prolonging hospital stay) 10 (6.5%) 0 (0.0%) 0.002
Figure 3 Bleeding complications (majorþminor, in per cent) among all study patients and among PCI patients only.
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16 recommend, that ‘every patient scheduled for
PCI should be considered for pre-treatment with clopidogrel at
least 6 h prior to the procedure with a dose of 300 mg ideally
administered the day before a planned PCI and if this is not poss-
ible a loading dose of 600 mg should be administered at least 2 h
before PCI’. However, only very few patients are actually scheduled
for elective PCI, most patients are scheduled for elective coronary
angiogram with immediate ‘ad hoc’ PCI procedure when indicated.
Thus, in the real life, only a few minutes elapse between the decision
to perform PCI and the beginning of the procedure. The rec-
ommended time window 2–6 h before PCI for pre-treatment
thus means that patients in many hospitals are actually pre-treated
before CAG, exposing thus the majority of patients (all who
undergo only CAG and not PCI) unnecessarily to aggressive
antiplatelet medication and potentially causing avoidable bleeding
complications. The ESC guidelines indirectly recommend this non-
selective clopidogrel treatment for all CAG patients by saying ‘If
diagnostic angiography is negative or no stenting was performed,
or if early heart surgery is indicated, clopidogrel can be stopped.’
This recommendation, however, was based only on empiric position
of the guidelines authors, the evidence was lacking.
Periprocedural ischaemic events
The incidence of periprocedural myocardial necrosis after PCI
largely varies depending on the study populations and methods
of detection. A recent study among patients with acute coronary
syndromes revealed to ‘biochemical’ periprocedural infarctions
among 43% of suboptimal responders to aspirin plus clopidogrel
vs. 22% among responders.
17 Chronic stable angina patients,
undergoing elective PCI were studied by Hochholzer et al.
18—
the 30-day incidence of clinically apparent MI was 1%. Another
study on consecutive PCI patients showed the 6% combined
major cardiovascular event (non-fatal MI, non-fatal ischaemic
stroke, or cardiovascular death) in patients who adequately
responded to clopidogrel.
19 Our study showed that among sub-
group of patients undergoing PCI, clopidogrel pre-treatment
.6 h before CAG/PCI did not signiﬁcantly reduce periprocedural
troponin elevation. Clinically signiﬁcant ‘ischaemic’ periprocedural
complications were few and equally distributed in both groups.
Stable coronary artery disease vs. acute
coronary syndromes
The well-known difference in platelet activity and also in overall
risk of ischaemic events between patients with acute coronary syn-
dromes and those with stable coronary artery disease can explain
somewhat surprising results of this study. Our results cannot be
extrapolated to patients with acute coronary syndromes, in
whom the beneﬁt from early clopidogrel therapy is unequivocal.
Periprocedural bleeding complications
In general, bleeding complications are rare in the elective CAG/PCI
patient population. Hochholzer et al.
20 found 0.5% major bleeding
rate within the group of 573 patients undergoing CAG at least 2 h
afteradministration of600 mg clopidogrel, who did not undergoPCI.
The CLopidogrel ASpirin Stent International Cooperative Study
(CLASSICS) was the ﬁrst randomized trial to evaluate a loading
dose of clopidogrel in coronary stenting. The 300 mg loading
dose was well tolerated, notably with no increased risk of
serious bleeding.
3 The incidence of major peripheral or bleeding
complications was low—1.5% for clopidogrel loading dose and
1.2% for clopidogrel 75 mg QD without loading dose.
3 Pre-
treatment with a higher (600 mg) dose of clopidogrel carried
1.6% risk of major bleeding in the ISAR–REACT study.
However, randomized trials generally exclude patients at highest
risk of bleeding and may therefore underestimate the true fre-
quency of bleeding associated with clopidogrel use in the general
population.
A subanalysis of 9478 patients with prior MI, ischaemic stroke,
or symptomatic peripheral arterial disease from the CHARISMA
trial
21 found no signiﬁcant difference in the rate of severe bleeding:
1.7% (aspirinþclopidogrel arm) vs. 1.5% (aspirinþplacebo arm),
while moderate bleeding was signiﬁcantly increased: 2.0 vs. 1.3%.
Despite the fact that using high dose (600 mg) of clopidogrel
very early (20.6 h) before procedure in our study, we probably
reached the platelet inhibition never reached before in any pre-
vious trial in chronic stable patients, the major bleedings were
only few. However, a small but signiﬁcant increase in minor bleed-
ing complications was the price paid for non-selective clopidogrel
use for all CAG patients in our study.
Cardiac surgeons do not like operating on patients with clopido-
grel on board. A recent study
22 showed double re-operations rate
among patients, who received clopidogrel 3 days prior to CABG.
However, this fear of cardiac surgeons from peri-operative bleed-
ing after clopidogrel is questioned by other studies.
23
An interesting Czech study
24 found 0.15% incidence (9 cases) of
gastrointestinal bleeding among 5955 patients hospitalized for elec-
tive CAG. However, the mortality of these patients was high (3/9,
i.e. 33%).
Study limitations
This was a randomized comparison of two unapproved (but rou-
tinely used in many centres worldwide) regimens of loading dose
of clopidogrel for PCI in stable angina. The approved loading
dose is 300 mg. The habit of giving a 600 mg loading dose
pre-PCI or at the time of PCI has spread among interventional car-
diologists, but without any clear evidence of its efﬁcacy and safety.
It could be possible that a 300 or 600 mg loading dose adminis-
tered long before angiography/PCI would probably not have
much difference on inhibition of platelet aggregation at the time
of PCI, but the impact on bleeding risk could be greater with
600 mg than with 300 mg.
This study was not designed to examine whether clopidogrel
should be used before PCI (we believe that the answer is yes).
This trial was designed to test the use of high dose clopidogrel
before elective CAG. We believe that there is a substantial
overlap in literature between the terms ‘elective PCI’ and ‘elective
CAG+possible PCI’. We ﬁrmly believe that terminology should
be uniﬁed in this ﬁeld as follows: Planned elective PCI, scheduled
PCI procedure in a patient with already known CAG result (i.e.
PCI done as a separate procedure from CAG). Ad hoc PCI rep-
resents PCI procedure performed immediately following CAG.
Planned elective CAG represents scheduled CAG procedure in a
patient with clinical presentation of various forms of coronary
Clopidogrel pre-treatment in stable angina 1501artery disease. In other words, the term ‘planned elective PCI’
should not be used for patients without known CAG result.
Conclusions
High dose clopidogrel before elective CAG increased the risk of
bleeding complications while the effect on the primary ischaemic
endpoint was not signiﬁcant. Clopidogrel can be administered
safely in the catheterization laboratory between CAG and PCI in
patients with chronic stable angina. We suppose that clopidogrel
should be used before ‘planned elective PCI’ as well as before
‘ad hoc PCI’, but not before ‘planned elective CAG’.
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